Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
about
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyRituximab for Rheumatoid Arthritis.Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsVariation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritisComparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.ptEvaluation of inconsistency in networks of interventionsClinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritisThe comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?Intracellular Signaling Pathways in Rheumatoid ArthritisTofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-AnalysisAutoimmune giant cell myocarditis: clinical characteristics, experimental models and future treatments.Nanotherapeutic approaches for the treatment of rheumatoid arthritis.Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Current immunotherapy in rheumatoid arthritis.Emerging cell and cytokine targets in rheumatoid arthritis.Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential.Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.Guidelines for the drug treatment of rheumatoid arthritis.Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings.
P2860
Q26824970-9E63D126-B22D-4330-BE9A-8EDD2FE7BB21Q27694496-EA00F0B7-242E-40E7-8A62-D883C8A84170Q28080246-6B81D7AF-7996-449E-82FE-24900BB5A72AQ28543128-07D3EA02-5EFA-47CE-9904-42B0410D87D4Q28545783-B9092A24-B0D0-480F-B00C-5E20897875F7Q30956564-8452F1EC-938A-4C93-8D34-5930CE1F942EQ33620679-35FC37DC-5245-4780-BC1B-E95E6CCBC03DQ34067792-07531F08-77B0-4709-AA1D-A8C046A2D9B4Q34183220-8A02BC4E-5270-4AE3-8E57-DFB8F0F6A185Q34401527-E7E0E50F-7165-4932-99DF-73FED7E4D646Q35038322-563A0416-ADCD-4781-80F0-943560CF11BEQ35048356-AE0EB69C-E2C0-4922-BA32-FA7F96B3D4DEQ35082559-BE38BF53-3C55-418A-9F4A-EFC53785D607Q35237316-737E8F09-0392-44CB-B5DA-1B9C6C4611C5Q35415667-A9779CDB-36C2-4EF5-BC72-640B880FDA1FQ35605438-8FB846F1-1AA2-488E-873A-FC48765E88B8Q35699981-641CCC07-1468-4ABE-B514-EC1323D4BE66Q35809549-17041A9B-B251-45F3-8D0E-F60BD653D694Q36036975-A633EAE8-38CA-4CE0-9349-CD62D6A06C7EQ36205166-65773039-D5B2-4F1E-8071-FCCCEAB936BFQ36378864-D154C8FB-0906-42E4-BCB1-F58C57F906E0Q37626617-F2E4DD41-F5C5-4C96-BB71-DF2EB91C8387Q37717012-8786F79D-8B3C-44C6-8394-FC1B6AAD8460Q37900643-B5500A20-2643-42B6-9386-58E339A69FC1Q37916426-ADF9BAF4-A5B0-4C9E-8ED7-68385545090FQ38061615-0FF5A110-3AA9-4AE1-94AC-28A26CE33C23Q38128726-607620CE-3EB9-4426-A77A-0457E3C069D7Q38133655-23422285-456B-42BA-BF26-137159310620Q38161794-3AAA4BA9-9BC6-4275-9FB9-F20F53581F21Q38182440-111F8FF5-CB0E-4568-8621-3C872FCE2391Q38807451-1482F77A-C1FD-4670-91E5-41ABF110C0D8Q41139422-B04599D5-F831-46B6-8C83-657EFADA84B9Q42135873-0881159A-B09E-4F11-94D7-0AB7E5B89943Q42578542-BF14052F-BFD8-45C7-AD4F-F22C3D3D519AQ43098450-1211844B-4896-4BD1-B694-5547754684FAQ43430988-377EFF77-79A0-42BB-B470-3121B5097F8FQ43473208-E1955B7E-9254-4051-9DCA-7040057A8188Q43675571-6E3DE766-AE6A-4E71-9EA0-140936982545Q43759995-20EE512D-93C5-4943-8946-B6BE303B0D48Q44622925-9D4C92F9-1DF5-48A6-968D-3B45F47565C6
P2860
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@en
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@nl
type
label
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@en
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@nl
prefLabel
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@en
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@nl
P2093
P921
P356
P1476
Indirect comparisons of the ef ...... factor agent: a meta-analysis
@en
P2093
Carine Salliot
Claire Bombardier
Edward Keystone
Wanruchada Katchamart
P304
P356
10.1136/ARD.2010.132134
P407
P50
P577
2010-11-19T00:00:00Z